The progress in cardiovascular diseases is not only evident in clinical advancements but also in the understanding of the complex mechanisms underlying these conditions. Research has elucidated the role of inflammation, genetics, and lifestyle factors in cardiovascular health, paving the way for more targeted and comprehensive interventions. Advances in genetics and genomics have enabled the identification of specific genetic markers associated with cardiovascular risk, facilitating early identification of individuals predisposed to certain conditions. Lifestyle medicine has gained prominence, emphasizing the impact of diet, exercise, and stress management on cardiovascular health. Additionally, progress in telemedicine and remote monitoring offers opportunities for enhanced patient care and early detection of potential issues. The growing emphasis on prevention and holistic approaches reflects a paradigm shift toward proactive cardiovascular healthcare. As progress continues, collaborative efforts among clinicians, researchers, and healthcare systems contribute to a future where cardiovascular diseases are not only better managed but also prevented, resulting in improved cardiovascular health on a global scale.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India